The liabilities of EQL Pharma with headquarters in Sweden amounted to Swedish kronor in 2024. The reported fiscal year ends on March 31.
Compared to 2020, this marks an increase of approximately Swedish kronor. The trend from 2020 to 2024 shows, furthermore, that this increase happened continuously.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Nasdaq Nordic. (April 13, 2026). Liabilities of EQL Pharma from 2020 to 2024 (in million Swedish kronor) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 15, 2026, from /statistics/1589864/eql-pharma-liabilities/
Nasdaq Nordic. "Liabilities of EQL Pharma from 2020 to 2024 (in million Swedish kronor)." Chart. April 13, 2026. ÌÇÐÄÆƽâ°æ. Accessed July 15, 2026. /statistics/1589864/eql-pharma-liabilities/
Nasdaq Nordic. (2026). Liabilities of EQL Pharma from 2020 to 2024 (in million Swedish kronor). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 15, 2026. /statistics/1589864/eql-pharma-liabilities/
Nasdaq Nordic. "Liabilities of Eql Pharma from 2020 to 2024 (in Million Swedish Kronor)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 13 Apr 2026, /statistics/1589864/eql-pharma-liabilities/
Nasdaq Nordic, Liabilities of EQL Pharma from 2020 to 2024 (in million Swedish kronor) ÌÇÐÄÆƽâ°æ, /statistics/1589864/eql-pharma-liabilities/ (last visited July 15, 2026)
Liabilities of EQL Pharma from 2020 to 2024 (in million Swedish kronor) [Graph], Nasdaq Nordic, April 13, 2026. [Online]. Available: /statistics/1589864/eql-pharma-liabilities/
